No Matches Found
No Matches Found
No Matches Found
Tongling Jieya Biologic Technology Co., Ltd.
Tongling Jieya Biologic Technology Hits Day Low Amid Price Pressure at CNY 27.02
Tongling Jieya Biologic Technology Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Despite recent short-term challenges, the company reported impressive annual net profit growth and record sales, benefiting from significantly reduced raw material costs. It operates within the FMCG sector with a fair valuation.
Tongling Jieya Biologic Technology Co., Ltd. Faces Challenges Amid Market Fluctuations
Tongling Jieya Biologic Technology Co., Ltd. reported disappointing financial results for the quarter ending March 2025, raising concerns about its operational resilience. Despite a decline in raw material costs, the company faces challenges beyond input expenses. Its low debt-equity ratio may provide some stability amid market volatility.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
